Stopping MS meds in inactive relapsing MS patients 55+
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests whether older adults (55+) with stable relapsing-remitting multiple sclerosis can safely stop their moderate-efficacy disease-modifying therapy. It aims to see if continuing treatment is still needed when the disease has been inactive for at least 5 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 55 or older
- Diagnosed with relapsing-remitting multiple sclerosis (RRMS) at least 5 years ago
- No relapses, stable MRI scans, and stable disability scores for the past 5 years
- Currently on a moderate-efficacy MS medication (like interferon, glatiramer acetate, dimethyl fumarate, or teriflunomide) for at least 5 years straight
- Willing to possibly stop your current MS medication and follow study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if it's safe to stop or reduce anti-CD20 treatment after several years of stable disease, compared to continuing it. It's for people with relapsing-remitting MS who are at least 40 years old and have had no MS activity for the past 3 years on anti-CD20 therapy.
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
This study helps doctors decide on the best MS treatment for you using an AI decision-support tool. You'll be part of a real-world evaluation of how this tool works when doctors are considering changing your MS medication.
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
Hear when a new Relapsing-remitting Multiple Sclerosis (RRMS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.